Clinical Trial Update: Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the p38 inhibitor AZD7624 in corticosteroid-resistant asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• AZD7624

Snippet

Sponsor: National Jewish Health | Conditions: Corticosteroid Resistant (CR) Asthmatics | Phase 2 | Status: COMPLETED